Earlier this month at the Keystone Symposia, Hypoxia: From Basic Mechanisms to Therapeutics, Dr Ayse Latif (pictured below) from the University of Manchester presented a poster entitled “Interrogating gynaecological cancer cell metabolism at different oxygen tensions reveals simvastatin as metabolic regulator”.
The poster describes the background of the study
Around 200,000 new cases of gynaecological cancers are diagnosed in Europe every year. Potentially 75% of these cancers could benefit from improved treatment regimes. Gynaecological cancer cells have an increased glycolysis rate and lactate concentration which have been suggested to predict increased likelihood of metastasis, resistance to therapy and reduced survival in patients. Lactate transport in cancer cells is carried out by members of the monocarboxylate transporter (MCT) family, notably MCT1/4. Thus, we hypothesized that pharmacologic inhibition of MCTs could improve treatment outcome by reducing glycolytic potential of these tumour cells… (To continue reading, click here).
Researchers at the University of Manchester used a Whitley i2 Instrument Workstation, housing a Seahorse XF Analyzer, connected to a Whitley H35 HEPA Hypoxystation. This allowed for the preparation of cell lines under hypoxic conditions and their subsequent transfer to the i2 for analysis in a CO2 free and controlled temperature environment without exposure to ambient conditions.